EARNIX
11.1.2023 18:37:39 CET | Business Wire | Press release
Earnix, the market-leading provider of mission-critical cloud-based intelligent real-time, dynamic pricing and rating solutions for insurers and banks, today announced it is appointing insurance and fintech industry veteran, Robin Gilthorpe, as its new Chief Executive Officer effective February 1, 2023. Mr. Gilthorpe will be taking over the helm from Mr. Udi Ziv, who served as the company’s CEO over the past six years.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230111005784/en/
Robin Gilthorpe, CEO, Earnix (Photo: Business Wire)
Robin Gilthorpe, a veteran of the finance and insurance industries, brings to the role over 25 years of experience as a successful business leader. Throughout his career, Mr. Gilthorpe has held numerous executive leadership roles at leading technology and insurance companies such as TIBCO, Vertexone, Watersmart Software, DataSynapse and ESW Capital. In his most recent role at Insurtech innovator Salty, Gilthorpe served as Chief Operating Officer, generating a nine-figure outcome in sale to CDK Global.
“I am thrilled to be joining Earnix at this crucial time in the global economy,” said Robin Gilthrope, incoming CEO at Earnix. “Financial services companies across the globe are seeking intelligent operations to ensure they can offer real-time, dynamic solutions, to better serve customers, enabling them to be more agile, nimble, attentive, and responsive. Today’s end-customer demands unparalleled experience, alongside highly personalized and customizable solutions. Earnix solutions serve as the go-to platform for financial services companies to address the growing demands of the world’s leading financial and insurance companies.”
His hiring comes on the heels of a period of growth for Earnix led by exiting CEO Udi Ziv. Mr. Ziv joined Earnix in 2017 and in his six years with the firm has led the company to consistent growth, achieving Unicorn status and important strategic alliances including forging the recently announced strategic partnership with Guidewire as well as engagements with USAA, MAPFRE, IAG, Liberty Mutual, US Bank, Lloyd’s Banking Group, and many more. Mr. Ziv built a strong team of leaders positioned to drive the company’s continued growth. Udi will serve as one of the industry experts on the Earnix Board of directors.
“We are proud to welcome Robin to the Earnix family, and believe that his experience in building global, international companies, alongside the growing demand for Earnix’s suite of real-time, dynamic, composable Intelligent InsurOps solutions, will lead Earnix to significant growth over the next few years, and bring Earnix to international market leadership, with its real-time operation platform for the largest insurance companies and banking institutions,” said Erel Margalit, JVP Founder & Executive Chairman and Earnix's Chairman of the Board, “We want to thank Udi for his important role, over the last few years. With its growing presence in North America, Europe, Asia Pacific, and Israel, Earnix will continue to strive to become the category leader, in the real-time AI usage-based insurance and banking industry.”
“I’ve very much enjoyed my tenure at Earnix, leading the company to consistent year over year growth, and strongly believe in our people and products as a change agent for financial services companies,” Udi Ziv, exiting CEO, Earnix, said. “I believe now is the time to move on to my next endeavor as the company prepares for its next stage of international expansion. I firmly believe I am leaving the company in very capable hands with Robin and expect that the company will continue the rapid global growth Earnix has experienced in the last few years.”
About Earnix
Earnix is the premier provider of mission-critical composable and cloud-based intelligent solutions across pricing, rating, underwriting, product personalization and telematics. These fully integrated solutions provide ultra-fast ROI and are designed to transform how global insurers and banks are run by unlocking value across all facets of the business. It has been innovating for Insurers and Banks since 2001 with customers in over 35 countries across six continents and offices in the Americas, Europe, Asia Pacific, and Israel. Earnix shareholders include JVP, Insight Partners, IGP, and Vintage Investment Partners.
For more information please visit: earnix.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230111005784/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
